BrainsWay Ltd.'s SEC filings document foreign private issuer current reports for a medical technology company focused on noninvasive neurostimulation for mental health disorders. Recent Form 6-K reports furnish press releases and investor materials covering Deep TMS commercialization, FDA-cleared indications, payer reimbursement policies, clinical data, financial results, operating guidance, and strategic investments in provider networks and related neurostimulation assets.
The filings also identify the company as a Form 20-F filer and reference registration statements on Form S-8 and Form F-3. Exhibits disclose capital-allocation activity, customer and reimbursement developments, risk-factor themes in investor materials, and formal updates on the business model built around leasing and selling Deep TMS systems.
BrainsWay Ltd. (BWAY) submitted a Form 6-K as a foreign private issuer, incorporating this report into its existing Form S-8 and Form F-3 registration statements filed in 2019, 2024, and 2025.
The report includes an exhibit titled “BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder.” This indicates that the company has begun its first clinical trial using the Deep TMS 360 system in the area of alcohol use disorder.
BrainsWay Ltd. furnished a Form 6-K reporting that it received FDA clearance for its Deep TMS therapy as an adjunct treatment for major depressive disorder (MDD) in adolescents aged 15 to 21. The update is provided as an exhibit to the report. The company also notes that this Form 6-K is incorporated by reference into its existing U.S. registration statements on Form S-8 and Form F-3.
BrainsWay Ltd. (BWAY) furnished a Form 6-K for November 2025, providing an Investor Deck as Exhibit 99.1. The report notes that the submission is a foreign private issuer filing under the Securities Exchange Act.
The company states that this Form 6-K is incorporated by reference into its existing registration statements: a Form S-8 filed April 22, 2019 and Forms F-3 filed July 22, 2024 and April 22, 2025. The filing itself contains no financial results or transaction details beyond the inclusion of the investor presentation.
BrainsWay Ltd., an Israel-based foreign private issuer, submitted a Form 6-K for November 2025. The report furnishes Exhibit 99.1, a press release titled “BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights.” The filing is incorporated by reference into the company’s existing Form S-8 and two Form F-3 registration statements and is signed by Chief Executive Officer Hadar Levy.
BrainsWay Ltd. furnished a Form 6-K. The filing includes an exhibit announcing a National Institutes of Health grant to a leading U.S. research team investigating accelerated Deep TMS for treatment of alcohol use disorder.
The report states this Form 6-K is incorporated by reference into the company’s Form S-8 and two Form F-3 registration statements.
Brainsway Ltd. reported the appointment of Kost Forer Gabbay & Kasierer, a certified public accounting firm in Israel and a member of Ernst & Young Global, as the companys independent auditors for 2025 and continuing until the next annual general meeting. The Board of Directors is authorized to set the auditors compensation. The filing records a vote tally of 19,070,493 and includes the signature of Ami Boehm.
Brainsway Ltd. submitted a Form 6-K reporting corporate documents and exhibits, and confirming it files annual reports on Form 20-F. The filing incorporates by reference the companys Registration Statement on Form S-8 (Registration No. 333-230979) and two Form F-3 registration statements (Registration Nos. 333-280934 and 333-286672) with respective filing dates of April 22, 2019, July 22, 2024, and April 22, 2025. An exhibit index lists a press release dated August 21, 2025, an Investment Agreement, a Call Option Agreement, Amended and Restated Articles of Association, and a Second Amended and Restated Investors Rights Agreement. The report is signed by Chief Executive Officer Hadar Levy.
Brainsway Ltd. submitted a Form 6-K reporting corporate documents and exhibits, and confirming it files annual reports on Form 20-F. The filing incorporates by reference the companys Registration Statement on Form S-8 (Registration No. 333-230979) and two Form F-3 registration statements (Registration Nos. 333-280934 and 333-286672) with respective filing dates of April 22, 2019, July 22, 2024, and April 22, 2025. An exhibit index lists a press release dated August 21, 2025, an Investment Agreement, a Call Option Agreement, Amended and Restated Articles of Association, and a Second Amended and Restated Investors Rights Agreement. The report is signed by Chief Executive Officer Hadar Levy.